Tom reports and edits European consumer health care industry news and analysis. Leading HBW Insight’s health and wellness coverage in Europe, he has been writing about the sector since 2013. Tom’s main focus is analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios. He also reports on regulatory topics such as novel foods and prescription-to-OTC switches.
Latest from Tom Gallen
Sweden's Moberg wants to introduce its onychomycosis treatment to the US but expects it will need to complete an additional study to win FDA approval.
A round up of the latest moves in Europe's consumer health market: Enzymatica appoints CEO; Haleon hires DACH marketing chief; Futura confirms interim CEO.
Galenica's Swiss consumer health business Verfora is reaping the rewards of its expansion in the complementary medicine market with a solid showing in the first half of the year.
Weaker than expected sales of OTC ED treatment Eroxon has led Futura to launch a review of the brand's future direction.
Like its peers, Bayer Consumer Health has struggled in the challenging US market in the first half of 2025 and says it doesn't expect conditions to change this year.
OTC sales grew at Italy's Recordati in the first half of 2025, with an improving cough and cold picture contributing to the rise.